- Home
- CASI vs SYBX Comparison
CASI vs SYBX Comparison
Compare CASI & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- SYBX
- Stock Information
- Founded
- CASI 1991
- SYBX N/A
- Country
- CASI China
- SYBX United States
- Employees
- CASI N/A
- SYBX N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- SYBX Health Care
- Exchange
- CASI Nasdaq
- SYBX Nasdaq
- Market Cap
- CASI 24.9M
- SYBX 20.0M
- IPO Year
- CASI 1996
- SYBX N/A
- Fundamental
- Price
- CASI $1.30
- SYBX $1.75
- Analyst Decision
- CASI Strong Buy
- SYBX
- Analyst Count
- CASI 1
- SYBX 0
- Target Price
- CASI $4.00
- SYBX N/A
- AVG Volume (30 Days)
- CASI 26.7K
- SYBX 50.2K
- Earning Date
- CASI 11-14-2025
- SYBX 11-11-2025
- Dividend Yield
- CASI N/A
- SYBX N/A
- EPS Growth
- CASI N/A
- SYBX N/A
- EPS
- CASI N/A
- SYBX N/A
- Revenue
- CASI $31,564,000.00
- SYBX N/A
- Revenue This Year
- CASI N/A
- SYBX N/A
- Revenue Next Year
- CASI N/A
- SYBX N/A
- P/E Ratio
- CASI N/A
- SYBX N/A
- Revenue Growth
- CASI 36.64
- SYBX N/A
- 52 Week Low
- CASI $1.09
- SYBX $0.90
- 52 Week High
- CASI $5.95
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- CASI 35.39
- SYBX 49.98
- Support Level
- CASI $1.29
- SYBX $1.52
- Resistance Level
- CASI $1.48
- SYBX $1.86
- Average True Range (ATR)
- CASI 0.13
- SYBX 0.12
- MACD
- CASI -0.00
- SYBX -0.01
- Stochastic Oscillator
- CASI 0.00
- SYBX 42.86
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.